XGN Exagen (XGN) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-medical laboratories · CIK 0001274737
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
23
13F, latest reported quarter
What the filings say about XGN
Insiders, 180 days
-$314.1K net sold
1 buyer · 2 sellers · 0% of sales under a 10b5-1 plan
Exagen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, EXAGEN INC. insiders sold a net $314.1K of stock across 27 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.5% of the 2,618,540 shares held after it.
- No other insider bought within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Chernett Jorey bought about $104.4K of XGN on Oct 19, 2026, the largest insider purchase at the company since 2022; 23 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (3 buys, 4 sales), the last on Mar 3, 2026.
- +49.0% median (+31.7% mean) 90-day return after 3 previous buys.
- The trade is 4.3% of the 805,540 shares held after it.
- No other insider sold within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO ABALLI JOHN sold about $269.8K of XGN on Oct 16, 2026, the largest insider sale at the company since 2025; 23 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Feb 24, 2026.
- The trade is 6.4% of the 323,339 shares held after it.
- No other insider sold within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Black Jeffrey G. sold about $148.8K of XGN on Sep 1, 2026; 23 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (3 buys, 3 sales), the last on Feb 24, 2026.
- +49.0% median (+31.7% mean) 90-day return after 3 previous buys.
- The trade is 2.3% of the 687,299 shares held after it.
- 1 other insider sold within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO ABALLI JOHN sold about $56.8K of XGN on Mar 3, 2026; 1 other insider sold within 30 days and 23 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (3 buys, 2 sales), the last on Oct 16, 2025.
- +49.0% median (+31.7% mean) 90-day return after 3 previous buys.
- The trade is 1.6% of the 702,997 shares held after it.
- 1 other insider sold within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO ABALLI JOHN sold about $41.3K of XGN on Feb 24, 2026; 1 other insider sold within 30 days and 23 funds added in the latest 13F quarter.27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$314.1K over 180 days
-$314.1K over 90 days · +$104.4K of it by a 10%+ holder
more than 65% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
23 funds bought in last quarter
below 82% of Healthcare Services
Revenue
+19.7% year over year
more than 67% of Healthcare Services
Margin
-30.0% net margin
below 78% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
6.1% of the float short (float per yahoo 2026-10-27) · 1.8 days to cover · settled 2026-10-15
below 54% of Healthcare Services
What changed in the last 30 days
Oct 20Insider Chernett Jorey bought $104.4K (Oct 19)
Oct 19President and CEO ABALLI JOHN sold $269.8K (Oct 16)
Watch XGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-34.7%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns XGN: institutional holders (13F)
13F holdings, latest reported quarter
792,855 sh
$3.7M
675,000 sh
$3.1M
613,930 sh
$2.9M
612,832 sh
$2.8M
596,528 sh
$2.8M
Congress trades in XGN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
XGN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
XGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
NORTH SQUARE KENNEDY MICROCAP FUND
$126.8K position · as of 2026-05-31
0.4%
Ultra-Small Company Market Fund
$115.3K position · as of 2026-06-30
0.1%
First Eagle Small Cap Opportunity Fund
$2.0M position · as of 2026-07-31
0.1%
GMO U.S. Small Cap Value Fund
$28.3K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$260.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$17.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · John Aballi
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.4M
$2.9M
$746.2K
+153%
n/a
2024
$1.2M
$2.0M
$905.7K
+68%
n/a
2023
$932.0K
$775.3K
$984.5K
-18%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $314.1K sold by insiders over 180 days, 23 funds added last quarter. Each figure is a federal filing, dated the day it went public.
XGN financials
Revenue growth
+19.7%
XBRL, annual
Net margin
-30.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$71.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM XGN
| FY Dec 2025 | $66.6M |
| FY Dec 2024 | $55.6M |
| FY Dec 2023 | $52.5M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $48.3M |
| Jun 2026 | $19.9M |
| Mar 2026 | $17.3M |
| Dec 2025 | $16.6M |
| Sep 2025 | $17.2M |
| Jun 2025 | $17.2M |
| Mar 2025 | $15.5M |
| Dec 2024 | $13.7M |
| Sep 2024 | $12.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-26.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM XGN
| FY Dec 2025 | -30.0% |
| FY Dec 2024 | -27.2% |
| FY Dec 2023 | -45.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -55.6% |
| Jun 2026 | -16.0% |
| Mar 2026 | -22.9% |
| Dec 2025 | -28.1% |
| Sep 2025 | -41.1% |
| Jun 2025 | -25.8% |
| Mar 2025 | -24.2% |
| Dec 2024 | -27.5% |
| Sep 2024 | -40.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM XGN
| FY Dec 2025 | -$14.3M |
| FY Dec 2024 | -$13.8M |
| FY Dec 2023 | -$15.3M |
| FY Dec 2022 | -$36.5M |
| FY Dec 2021 | -$22.6M |
| Jun 2026 | $3.4M |
| Mar 2026 | -$10.6M |
| Dec 2025 | -$3.1M |
| Sep 2025 | $2.7M |
| Jun 2025 | -$3.1M |
| Mar 2025 | -$10.8M |
| Dec 2024 | $217.0K |
| Sep 2024 | -$2.3M |
At each fiscal year end
Single quarter
Debt to equity
1.87x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity XGN
| FY Dec 2025 | 1.31x |
| FY Dec 2024 | 2.12x |
| FY Dec 2023 | 0.86x |
| FY Dec 2022 | 0.68x |
| FY Dec 2021 | 0.32x |
| Jun 2026 | 1.87x |
| Mar 2026 | 1.58x |
| Dec 2025 | 1.31x |
| Sep 2025 | 1.26x |
| Jun 2025 | 1.09x |
| Mar 2025 | 3.27x |
| Dec 2024 | 2.12x |
| Sep 2024 | 1.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.28x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt XGN
| FY Dec 2025 | -0.59x |
| FY Dec 2024 | -0.66x |
| FY Dec 2023 | -0.74x |
| FY Dec 2022 | -1.11x |
| FY Dec 2021 | -0.74x |
| Jun 2026 | -0.28x |
| Mar 2026 | -0.58x |
| Dec 2025 | -0.59x |
| Sep 2025 | -0.45x |
| Jun 2025 | -0.67x |
| Mar 2025 | -0.71x |
| Dec 2024 | -0.66x |
| Sep 2024 | -0.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-113.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity XGN
| FY Dec 2025 | -147.8% |
| FY Dec 2024 | -93.8% |
| FY Dec 2023 | -72.7% |
| FY Dec 2022 | -74.4% |
| FY Dec 2021 | -42.4% |
| Jun 2026 | -113.8% |
| Mar 2026 | -193.6% |
| Dec 2025 | -147.8% |
| Sep 2025 | -122.8% |
| Jun 2025 | -87.9% |
| Mar 2025 | -117.5% |
| Dec 2024 | -93.8% |
| Sep 2024 | -83.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-34.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets XGN
| FY Dec 2025 | -38.8% |
| FY Dec 2024 | -29.7% |
| FY Dec 2023 | -33.1% |
| FY Dec 2022 | -45.2% |
| FY Dec 2021 | -26.6% |
| Jun 2026 | -34.2% |
| Mar 2026 | -43.7% |
| Dec 2025 | -38.8% |
| Sep 2025 | -35.8% |
| Jun 2025 | -31.4% |
| Mar 2025 | -34.0% |
| Dec 2024 | -29.7% |
| Sep 2024 | -32.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital XGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-30.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed XGN
| FY Dec 2025 | -37.5% |
| FY Dec 2024 | -35.8% |
| FY Dec 2023 | -37.5% |
| FY Dec 2022 | -48.3% |
| FY Dec 2021 | -26.2% |
| Jun 2026 | -30.4% |
| Mar 2026 | -43.0% |
| Dec 2025 | -37.5% |
| Sep 2025 | -29.4% |
| Jun 2025 | -31.8% |
| Mar 2025 | -41.0% |
| Dec 2024 | -35.8% |
| Sep 2024 | -36.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing XGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$186.7M
market value at close 2026-10-27 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value XGN
| FY Dec 2025 | $128.5M |
| FY Dec 2024 | $70.5M |
| FY Dec 2023 | $16.9M |
| FY Dec 2022 | $5.7M |
| FY Dec 2021 | $116.0M |
| Jun 2026 | $110.6M |
| Mar 2026 | $73.5M |
| Dec 2025 | $128.5M |
| Sep 2025 | $229.1M |
| Jun 2025 | $118.6M |
| Mar 2025 | $74.0M |
| Dec 2024 | $70.5M |
| Sep 2024 | $51.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-4.0%
TTM free cash flow over market value at close 2026-10-27
FCF yield XGN
| FY Dec 2025 | -10.4% |
| FY Dec 2024 | -19.1% |
| FY Dec 2023 | -45.1% |
| FY Dec 2022 | -93.1% |
| FY Dec 2021 | -12.0% |
| Jun 2026 | -6.8% |
| Mar 2026 | -19.6% |
| Dec 2025 | -10.4% |
| Sep 2025 | -4.5% |
| Jun 2025 | -12.7% |
| Mar 2025 | -24.0% |
| Dec 2024 | -19.1% |
| Sep 2024 | -10.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing XGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $66.6M | $55.6M | $52.5M | $45.6M |
| Gross profit | $38.8M | $33.1M | $29.5M | n/a |
| Operating income | -$14.1M | -$13.6M | -$22.8M | -$46.1M |
| Net income | -$20.0M | -$15.1M | -$23.7M | -$47.4M |
| EPS (diluted) | -0.93 | -0.83 | -1.34 | -2.77 |
| Operating cash flow | -$13.6M | -$13.3M | -$14.5M | -$32.1M |
| Cash | $32.2M | $22.0M | $36.5M | $62.4M |
| Long-term debt | $22.3M | $19.8M | $19.2M | $28.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
XGN Stock Sonar score 6/7 axes
Find similar shapesCompareXGN ranks highest on growth (67th percentile) and insider conviction (63rd), and lowest on institutional and government (18th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
XGN filings, in plain words
Are Exagen insiders buying or selling XGN?
In the 180 days to 2026-10-28, Exagen insiders were net sellers, a net $314.1K: $104.4K of purchases and $418.6K of sales reported on Form 4, by 1 buyer and 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, Exagen insiders were net sellers of XGN, a net $314.1K across purchases and sales reported on Form 4 by 1 buyer and 2 sellers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
